Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review
F Huguet, N Girard, CSE Guerche… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At
time of diagnosis, 30% of patients present with a locally advanced unresectable but …
time of diagnosis, 30% of patients present with a locally advanced unresectable but …
Acute leukemia during pregnancy: a report on 37 patients and a review of the literature
Y Chelghoum, N Vey, E Raffoux, F Huguet, A Pigneux… - Cancer, 2005 - Wiley Online Library
BACKGROUND Acute leukemia (AL) requiring cytotoxic treatment occurring during
pregnancy poses a very difficult therapeutic dilemma. METHODS By means of a mail …
pregnancy poses a very difficult therapeutic dilemma. METHODS By means of a mail …
Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT …
…, T Conroy, L Dahan, M Gilabert, F Huguet… - Digestive and Liver …, 2018 - Elsevier
Background This document is a summary of the French intergroup guidelines regarding the
management of pancreatic adenocarcinoma (PA), updated in July 2018. Design This …
management of pancreatic adenocarcinoma (PA), updated in July 2018. Design This …
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective …
FX Mahon, D Réa, J Guilhot, F Guilhot, F Huguet… - The lancet …, 2010 - thelancet.com
Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
myeloid leukaemia (CML), but little is known about whether treatment can safely be …
[HTML][HTML] Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
…, R Pasquini, H Nakamae, F Huguet… - … England Journal of …, 2010 - Mass Medical Soc
Background Treatment with dasatinib, a highly potent BCR-ABL kinase inhibitor, has
resulted in high rates of complete cytogenetic response and progression-free survival …
resulted in high rates of complete cytogenetic response and progression-free survival …
Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without …
Importance In locally advanced pancreatic cancer, the role of chemoradiotherapy is
controversial and the efficacy of erlotinib is unknown. Objectives To assess whether …
controversial and the efficacy of erlotinib is unknown. Objectives To assess whether …
A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly …
…, M Fey, C Rayon, F Huguet… - Blood, The Journal …, 1999 - ashpublications.org
All transretinoic acid (ATRA) followed by daunorubicin (DNR)-AraC chemotherapy (CT) has
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …
improved the outcome of acute promyelocytic leukemia (APL) by comparison to CT alone. In …
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
P Rousselot, F Huguet, D Rea, L Legros, JM Cayuela… - Blood, 2007 - ashpublications.org
In the present study, we address the issue of the discontinuation of imatinib mesylate
(Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more …
(Gleevec) in chronic myelogenous leukemia with undetectable residual disease for more …
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non …
…, G Etienne, J Dengler, F Huguet… - The Lancet …, 2018 - thelancet.com
Summary Background Tyrosine kinase inhibitors (TKIs) have improved the survival of
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a …
[PDF][PDF] Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies
Purpose The management of locally advanced (LA) pancreatic cancer patients remains
controversial. To select patients who could benefit from chemoradiotherapy (CRT), the …
controversial. To select patients who could benefit from chemoradiotherapy (CRT), the …